Global Cell Therapy for Solid Tumor Market 2026 by Company, Regions, Type and Application, Forecast to 2032
According to our (Global Info Research) latest study, the global Cell Therapy for Solid Tumor market size was valued at US$ 2074 million in 2025 and is forecast to a readjusted size of US$ 7768 million by 2032 with a CAGR of 19.7% during review period.
Cell Therapy for Solid Tumors refers to innovative biological therapies that use autologous or donor-derived immune cells, which are isolated, selected, expanded, genetically engineered, or functionally enhanced ex vivo and then reinfused into the patient to recognize, infiltrate, and kill solid tumor cells. This field includes tumor-infiltrating lymphocyte therapy, TCR-T cell therapy, CAR-T cell therapy, CAR-NK/NK cell therapy, and other engineered immune cell approaches, targeting solid tumors such as melanoma, lung cancer, liver cancer, gastrointestinal cancers, gynecologic tumors, sarcomas, and other refractory or relapsed malignancies. Compared with cell therapies for hematologic cancers, solid tumor cell therapy must overcome major barriers including tumor heterogeneity, antigen selection, immunosuppressive microenvironments, cell infiltration, and in vivo persistence. It represents a frontier direction in expanding cancer immunotherapy from blood cancers to the broader solid tumor market.The average gross profit margin of this product is 90%.
Cell therapy for solid tumors is at a critical inflection point, moving from clinical exploration toward commercial validation. With TIL therapy and engineered T cell therapies achieving regulatory breakthroughs in solid tumor indications, industry confidence is shifting from ?conceptually feasible? to ?clinically translatable and commercially actionable.? Solid tumors represent a broad patient population with high relapse and refractory rates, and substantial unmet needs remain after surgery, radiotherapy, chemotherapy, targeted therapy, and immune checkpoint inhibitors, creating an attractive market entry point for cell therapy. At the same time, advances in single-cell sequencing, tumor antigen discovery, TCR screening, gene editing, cell expansion, and cold-chain logistics are pushing companies from single-product development toward platform-based strategies. For CEOs, marketing leaders, and investors, cell therapy for solid tumors is not only a next-generation oncology innovation field, but also a strategic industrial opportunity connecting precision diagnostics, cell manufacturing, hospital treatment centers, and long-term patient management.
The challenges of cell therapy for solid tumors are concentrated in scientific, manufacturing, and clinical complexity. Solid tumors are highly heterogeneous, tumor antigen expression can be unstable, and low-level antigen expression in normal tissues may create off-target risks. The tumor microenvironment, including immunosuppressive cells, hypoxia, fibrotic barriers, and metabolic stress, can limit therapeutic cell infiltration and sustained killing activity. On the manufacturing side, autologous cell products involve significant batch-to-batch variability, long production cycles, and strict release testing, placing high demands on process robustness, quality systems, and supply chain coordination. Commercially, companies must also address treatment-center development, physician training, adverse event management, patient screening, reimbursement systems, and treatment accessibility. Future competition will not be determined only by individual clinical results, but by whether companies can systematically solve challenges across target selection, cell engineering, scalable manufacturing, and clinical delivery.
Downstream demand for cell therapy in solid tumors will gradually expand from late-line, relapsed, and refractory patients toward more precise stratification and earlier-line treatment strategies. Oncology hospitals, comprehensive cancer centers, cell therapy centers, clinical research institutions, and regional medical centers are the most important application settings at the current stage. As companion diagnostics, HLA typing, tumor antigen testing, and cell therapy center capabilities mature, downstream customers will shift their focus from ?whether it works? to ?which patients are suitable, whether the treatment workflow is controllable, whether responses are durable, whether safety is manageable, and whether it can be combined with immunotherapy or targeted therapy.? Cell therapy for solid tumors will no longer be viewed only as a last-line option, but may become a high-value module in multidisciplinary oncology treatment. Companies with clear indication positioning, strong clinical evidence, and treatment-center collaboration capabilities will be better positioned to build brand trust and market access advantages.
This report is a detailed and comprehensive analysis for global Cell Therapy for Solid Tumor market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Cell Therapy for Solid Tumor market size and forecasts, in consumption value ($ Million), 2021-2032
Global Cell Therapy for Solid Tumor market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Cell Therapy for Solid Tumor market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Cell Therapy for Solid Tumor market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Cell Therapy for Solid Tumor market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Cell Therapy for Solid Tumors refers to innovative biological therapies that use autologous or donor-derived immune cells, which are isolated, selected, expanded, genetically engineered, or functionally enhanced ex vivo and then reinfused into the patient to recognize, infiltrate, and kill solid tumor cells. This field includes tumor-infiltrating lymphocyte therapy, TCR-T cell therapy, CAR-T cell therapy, CAR-NK/NK cell therapy, and other engineered immune cell approaches, targeting solid tumors such as melanoma, lung cancer, liver cancer, gastrointestinal cancers, gynecologic tumors, sarcomas, and other refractory or relapsed malignancies. Compared with cell therapies for hematologic cancers, solid tumor cell therapy must overcome major barriers including tumor heterogeneity, antigen selection, immunosuppressive microenvironments, cell infiltration, and in vivo persistence. It represents a frontier direction in expanding cancer immunotherapy from blood cancers to the broader solid tumor market.The average gross profit margin of this product is 90%.
Cell therapy for solid tumors is at a critical inflection point, moving from clinical exploration toward commercial validation. With TIL therapy and engineered T cell therapies achieving regulatory breakthroughs in solid tumor indications, industry confidence is shifting from ?conceptually feasible? to ?clinically translatable and commercially actionable.? Solid tumors represent a broad patient population with high relapse and refractory rates, and substantial unmet needs remain after surgery, radiotherapy, chemotherapy, targeted therapy, and immune checkpoint inhibitors, creating an attractive market entry point for cell therapy. At the same time, advances in single-cell sequencing, tumor antigen discovery, TCR screening, gene editing, cell expansion, and cold-chain logistics are pushing companies from single-product development toward platform-based strategies. For CEOs, marketing leaders, and investors, cell therapy for solid tumors is not only a next-generation oncology innovation field, but also a strategic industrial opportunity connecting precision diagnostics, cell manufacturing, hospital treatment centers, and long-term patient management.
The challenges of cell therapy for solid tumors are concentrated in scientific, manufacturing, and clinical complexity. Solid tumors are highly heterogeneous, tumor antigen expression can be unstable, and low-level antigen expression in normal tissues may create off-target risks. The tumor microenvironment, including immunosuppressive cells, hypoxia, fibrotic barriers, and metabolic stress, can limit therapeutic cell infiltration and sustained killing activity. On the manufacturing side, autologous cell products involve significant batch-to-batch variability, long production cycles, and strict release testing, placing high demands on process robustness, quality systems, and supply chain coordination. Commercially, companies must also address treatment-center development, physician training, adverse event management, patient screening, reimbursement systems, and treatment accessibility. Future competition will not be determined only by individual clinical results, but by whether companies can systematically solve challenges across target selection, cell engineering, scalable manufacturing, and clinical delivery.
Downstream demand for cell therapy in solid tumors will gradually expand from late-line, relapsed, and refractory patients toward more precise stratification and earlier-line treatment strategies. Oncology hospitals, comprehensive cancer centers, cell therapy centers, clinical research institutions, and regional medical centers are the most important application settings at the current stage. As companion diagnostics, HLA typing, tumor antigen testing, and cell therapy center capabilities mature, downstream customers will shift their focus from ?whether it works? to ?which patients are suitable, whether the treatment workflow is controllable, whether responses are durable, whether safety is manageable, and whether it can be combined with immunotherapy or targeted therapy.? Cell therapy for solid tumors will no longer be viewed only as a last-line option, but may become a high-value module in multidisciplinary oncology treatment. Companies with clear indication positioning, strong clinical evidence, and treatment-center collaboration capabilities will be better positioned to build brand trust and market access advantages.
This report is a detailed and comprehensive analysis for global Cell Therapy for Solid Tumor market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Cell Therapy for Solid Tumor market size and forecasts, in consumption value ($ Million), 2021-2032
Global Cell Therapy for Solid Tumor market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Cell Therapy for Solid Tumor market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Cell Therapy for Solid Tumor market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
- To determine the size of the total market opportunity of global and key countries
- To assess the growth potential for Cell Therapy for Solid Tumor
- To forecast future growth in each product and end-use market
- To assess competitive factors affecting the marketplace
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Cell Therapy for Solid Tumor market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- CAR-T Therapy
- TCR-T Therapy
- TIL Therapy
- CAR-NK Therapy
- Tumor-Infiltrating NK Or T Cells
- Other
- Autologous Therapy
- Allogeneic Therapy
- Gene-Edited Therapy
- Armored Cell Therapy
- Combination Therapy
- Other
- Melanoma Products
- Gastrointestinal Tumor Products
- Liver Cancer Products
- Lung Cancer Products
- Gynecologic Tumor Products
- Other
- Melanoma
- Lung Cancer
- Liver Cancer
- Gastric And Colorectal Cancer
- Ovarian Cancer
- Other
- Iovance Biotherapeutics
- Adaptimmune
- Immatics
- CARSgen Therapeutics
- JW Therapeutics
- Legend Biotech
- Gracell Biotechnologies
- Fosun Kite
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
- Chapter 1, to describe Cell Therapy for Solid Tumor product scope, market overview, market estimation caveats and base year.
- Chapter 2, to profile the top players of Cell Therapy for Solid Tumor, with revenue, gross margin, and global market share of Cell Therapy for Solid Tumor from 2021 to 2026.
- Chapter 3, the Cell Therapy for Solid Tumor competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
- Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
- Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Cell Therapy for Solid Tumor market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
- Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
- Chapter 12, the key raw materials and key suppliers, and industry chain of Cell Therapy for Solid Tumor.
- Chapter 13, to describe Cell Therapy for Solid Tumor research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Cell Therapy for Solid Tumor by Type
1.3.1 Overview: Global Cell Therapy for Solid Tumor Market Size by Type: 2021 Versus 2025 Versus 2032
1.3.2 Global Cell Therapy for Solid Tumor Consumption Value Market Share by Type in 2025
1.3.3 CAR-T Therapy
1.3.4 TCR-T Therapy
1.3.5 TIL Therapy
1.3.6 CAR-NK Therapy
1.3.7 Tumor-Infiltrating NK Or T Cells
1.3.8 Other
1.4 Classification of Cell Therapy for Solid Tumor by Cell Source
1.4.1 Overview: Global Cell Therapy for Solid Tumor Market Size by Cell Source: 2021 Versus 2025 Versus 2032
1.4.2 Global Cell Therapy for Solid Tumor Consumption Value Market Share by Cell Source in 2025
1.4.3 Autologous Therapy
1.4.4 Allogeneic Therapy
1.4.5 Gene-Edited Therapy
1.4.6 Armored Cell Therapy
1.4.7 Combination Therapy
1.4.8 Other
1.5 Classification of Cell Therapy for Solid Tumor by Indication
1.5.1 Overview: Global Cell Therapy for Solid Tumor Market Size by Indication: 2021 Versus 2025 Versus 2032
1.5.2 Global Cell Therapy for Solid Tumor Consumption Value Market Share by Indication in 2025
1.5.3 Melanoma Products
1.5.4 Gastrointestinal Tumor Products
1.5.5 Liver Cancer Products
1.5.6 Lung Cancer Products
1.5.7 Gynecologic Tumor Products
1.5.8 Other
1.6 Global Cell Therapy for Solid Tumor Market by Application
1.6.1 Overview: Global Cell Therapy for Solid Tumor Market Size by Application: 2021 Versus 2025 Versus 2032
1.6.2 Melanoma
1.6.3 Lung Cancer
1.6.4 Liver Cancer
1.6.5 Gastric And Colorectal Cancer
1.6.6 Ovarian Cancer
1.6.7 Other
1.7 Global Cell Therapy for Solid Tumor Market Size & Forecast
1.8 Global Cell Therapy for Solid Tumor Market Size and Forecast by Region
1.8.1 Global Cell Therapy for Solid Tumor Market Size by Region: 2021 VS 2025 VS 2032
1.8.2 Global Cell Therapy for Solid Tumor Market Size by Region, (2021-2032)
1.8.3 North America Cell Therapy for Solid Tumor Market Size and Prospect (2021-2032)
1.8.4 Europe Cell Therapy for Solid Tumor Market Size and Prospect (2021-2032)
1.8.5 Asia-Pacific Cell Therapy for Solid Tumor Market Size and Prospect (2021-2032)
1.8.6 South America Cell Therapy for Solid Tumor Market Size and Prospect (2021-2032)
1.8.7 Middle East & Africa Cell Therapy for Solid Tumor Market Size and Prospect (2021-2032)
2 COMPANY PROFILES
2.1 Iovance Biotherapeutics
2.1.1 Iovance Biotherapeutics Details
2.1.2 Iovance Biotherapeutics Major Business
2.1.3 Iovance Biotherapeutics Cell Therapy for Solid Tumor Product and Solutions
2.1.4 Iovance Biotherapeutics Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Iovance Biotherapeutics Recent Developments and Future Plans
2.2 Adaptimmune
2.2.1 Adaptimmune Details
2.2.2 Adaptimmune Major Business
2.2.3 Adaptimmune Cell Therapy for Solid Tumor Product and Solutions
2.2.4 Adaptimmune Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Adaptimmune Recent Developments and Future Plans
2.3 Immatics
2.3.1 Immatics Details
2.3.2 Immatics Major Business
2.3.3 Immatics Cell Therapy for Solid Tumor Product and Solutions
2.3.4 Immatics Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Immatics Recent Developments and Future Plans
2.4 CARSgen Therapeutics
2.4.1 CARSgen Therapeutics Details
2.4.2 CARSgen Therapeutics Major Business
2.4.3 CARSgen Therapeutics Cell Therapy for Solid Tumor Product and Solutions
2.4.4 CARSgen Therapeutics Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 CARSgen Therapeutics Recent Developments and Future Plans
2.5 JW Therapeutics
2.5.1 JW Therapeutics Details
2.5.2 JW Therapeutics Major Business
2.5.3 JW Therapeutics Cell Therapy for Solid Tumor Product and Solutions
2.5.4 JW Therapeutics Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 JW Therapeutics Recent Developments and Future Plans
2.6 Legend Biotech
2.6.1 Legend Biotech Details
2.6.2 Legend Biotech Major Business
2.6.3 Legend Biotech Cell Therapy for Solid Tumor Product and Solutions
2.6.4 Legend Biotech Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 Legend Biotech Recent Developments and Future Plans
2.7 Gracell Biotechnologies
2.7.1 Gracell Biotechnologies Details
2.7.2 Gracell Biotechnologies Major Business
2.7.3 Gracell Biotechnologies Cell Therapy for Solid Tumor Product and Solutions
2.7.4 Gracell Biotechnologies Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 Gracell Biotechnologies Recent Developments and Future Plans
2.8 Fosun Kite
2.8.1 Fosun Kite Details
2.8.2 Fosun Kite Major Business
2.8.3 Fosun Kite Cell Therapy for Solid Tumor Product and Solutions
2.8.4 Fosun Kite Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 Fosun Kite Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Cell Therapy for Solid Tumor Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
3.2.1 Market Share of Cell Therapy for Solid Tumor by Company Revenue
3.2.2 Top 3 Cell Therapy for Solid Tumor Players Market Share in 2025
3.2.3 Top 6 Cell Therapy for Solid Tumor Players Market Share in 2025
3.3 Cell Therapy for Solid Tumor Market: Overall Company Footprint Analysis
3.3.1 Cell Therapy for Solid Tumor Market: Region Footprint
3.3.2 Cell Therapy for Solid Tumor Market: Company Product Type Footprint
3.3.3 Cell Therapy for Solid Tumor Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Cell Therapy for Solid Tumor Consumption Value and Market Share by Type (2021-2026)
4.2 Global Cell Therapy for Solid Tumor Market Forecast by Type (2027-2032)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Cell Therapy for Solid Tumor Consumption Value Market Share by Application (2021-2026)
5.2 Global Cell Therapy for Solid Tumor Market Forecast by Application (2027-2032)
6 NORTH AMERICA
6.1 North America Cell Therapy for Solid Tumor Consumption Value by Type (2021-2032)
6.2 North America Cell Therapy for Solid Tumor Market Size by Application (2021-2032)
6.3 North America Cell Therapy for Solid Tumor Market Size by Country
6.3.1 North America Cell Therapy for Solid Tumor Consumption Value by Country (2021-2032)
6.3.2 United States Cell Therapy for Solid Tumor Market Size and Forecast (2021-2032)
6.3.3 Canada Cell Therapy for Solid Tumor Market Size and Forecast (2021-2032)
6.3.4 Mexico Cell Therapy for Solid Tumor Market Size and Forecast (2021-2032)
7 EUROPE
7.1 Europe Cell Therapy for Solid Tumor Consumption Value by Type (2021-2032)
7.2 Europe Cell Therapy for Solid Tumor Consumption Value by Application (2021-2032)
7.3 Europe Cell Therapy for Solid Tumor Market Size by Country
7.3.1 Europe Cell Therapy for Solid Tumor Consumption Value by Country (2021-2032)
7.3.2 Germany Cell Therapy for Solid Tumor Market Size and Forecast (2021-2032)
7.3.3 France Cell Therapy for Solid Tumor Market Size and Forecast (2021-2032)
7.3.4 United Kingdom Cell Therapy for Solid Tumor Market Size and Forecast (2021-2032)
7.3.5 Russia Cell Therapy for Solid Tumor Market Size and Forecast (2021-2032)
7.3.6 Italy Cell Therapy for Solid Tumor Market Size and Forecast (2021-2032)
8 ASIA-PACIFIC
8.1 Asia-Pacific Cell Therapy for Solid Tumor Consumption Value by Type (2021-2032)
8.2 Asia-Pacific Cell Therapy for Solid Tumor Consumption Value by Application (2021-2032)
8.3 Asia-Pacific Cell Therapy for Solid Tumor Market Size by Region
8.3.1 Asia-Pacific Cell Therapy for Solid Tumor Consumption Value by Region (2021-2032)
8.3.2 China Cell Therapy for Solid Tumor Market Size and Forecast (2021-2032)
8.3.3 Japan Cell Therapy for Solid Tumor Market Size and Forecast (2021-2032)
8.3.4 South Korea Cell Therapy for Solid Tumor Market Size and Forecast (2021-2032)
8.3.5 India Cell Therapy for Solid Tumor Market Size and Forecast (2021-2032)
8.3.6 Southeast Asia Cell Therapy for Solid Tumor Market Size and Forecast (2021-2032)
8.3.7 Australia Cell Therapy for Solid Tumor Market Size and Forecast (2021-2032)
9 SOUTH AMERICA
9.1 South America Cell Therapy for Solid Tumor Consumption Value by Type (2021-2032)
9.2 South America Cell Therapy for Solid Tumor Consumption Value by Application (2021-2032)
9.3 South America Cell Therapy for Solid Tumor Market Size by Country
9.3.1 South America Cell Therapy for Solid Tumor Consumption Value by Country (2021-2032)
9.3.2 Brazil Cell Therapy for Solid Tumor Market Size and Forecast (2021-2032)
9.3.3 Argentina Cell Therapy for Solid Tumor Market Size and Forecast (2021-2032)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Cell Therapy for Solid Tumor Consumption Value by Type (2021-2032)
10.2 Middle East & Africa Cell Therapy for Solid Tumor Consumption Value by Application (2021-2032)
10.3 Middle East & Africa Cell Therapy for Solid Tumor Market Size by Country
10.3.1 Middle East & Africa Cell Therapy for Solid Tumor Consumption Value by Country (2021-2032)
10.3.2 Turkey Cell Therapy for Solid Tumor Market Size and Forecast (2021-2032)
10.3.3 Saudi Arabia Cell Therapy for Solid Tumor Market Size and Forecast (2021-2032)
10.3.4 UAE Cell Therapy for Solid Tumor Market Size and Forecast (2021-2032)
11 MARKET DYNAMICS
11.1 Cell Therapy for Solid Tumor Market Drivers
11.2 Cell Therapy for Solid Tumor Market Restraints
11.3 Cell Therapy for Solid Tumor Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Cell Therapy for Solid Tumor Industry Chain
12.2 Cell Therapy for Solid Tumor Upstream Analysis
12.3 Cell Therapy for Solid Tumor Midstream Analysis
12.4 Cell Therapy for Solid Tumor Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Cell Therapy for Solid Tumor by Type
1.3.1 Overview: Global Cell Therapy for Solid Tumor Market Size by Type: 2021 Versus 2025 Versus 2032
1.3.2 Global Cell Therapy for Solid Tumor Consumption Value Market Share by Type in 2025
1.3.3 CAR-T Therapy
1.3.4 TCR-T Therapy
1.3.5 TIL Therapy
1.3.6 CAR-NK Therapy
1.3.7 Tumor-Infiltrating NK Or T Cells
1.3.8 Other
1.4 Classification of Cell Therapy for Solid Tumor by Cell Source
1.4.1 Overview: Global Cell Therapy for Solid Tumor Market Size by Cell Source: 2021 Versus 2025 Versus 2032
1.4.2 Global Cell Therapy for Solid Tumor Consumption Value Market Share by Cell Source in 2025
1.4.3 Autologous Therapy
1.4.4 Allogeneic Therapy
1.4.5 Gene-Edited Therapy
1.4.6 Armored Cell Therapy
1.4.7 Combination Therapy
1.4.8 Other
1.5 Classification of Cell Therapy for Solid Tumor by Indication
1.5.1 Overview: Global Cell Therapy for Solid Tumor Market Size by Indication: 2021 Versus 2025 Versus 2032
1.5.2 Global Cell Therapy for Solid Tumor Consumption Value Market Share by Indication in 2025
1.5.3 Melanoma Products
1.5.4 Gastrointestinal Tumor Products
1.5.5 Liver Cancer Products
1.5.6 Lung Cancer Products
1.5.7 Gynecologic Tumor Products
1.5.8 Other
1.6 Global Cell Therapy for Solid Tumor Market by Application
1.6.1 Overview: Global Cell Therapy for Solid Tumor Market Size by Application: 2021 Versus 2025 Versus 2032
1.6.2 Melanoma
1.6.3 Lung Cancer
1.6.4 Liver Cancer
1.6.5 Gastric And Colorectal Cancer
1.6.6 Ovarian Cancer
1.6.7 Other
1.7 Global Cell Therapy for Solid Tumor Market Size & Forecast
1.8 Global Cell Therapy for Solid Tumor Market Size and Forecast by Region
1.8.1 Global Cell Therapy for Solid Tumor Market Size by Region: 2021 VS 2025 VS 2032
1.8.2 Global Cell Therapy for Solid Tumor Market Size by Region, (2021-2032)
1.8.3 North America Cell Therapy for Solid Tumor Market Size and Prospect (2021-2032)
1.8.4 Europe Cell Therapy for Solid Tumor Market Size and Prospect (2021-2032)
1.8.5 Asia-Pacific Cell Therapy for Solid Tumor Market Size and Prospect (2021-2032)
1.8.6 South America Cell Therapy for Solid Tumor Market Size and Prospect (2021-2032)
1.8.7 Middle East & Africa Cell Therapy for Solid Tumor Market Size and Prospect (2021-2032)
2 COMPANY PROFILES
2.1 Iovance Biotherapeutics
2.1.1 Iovance Biotherapeutics Details
2.1.2 Iovance Biotherapeutics Major Business
2.1.3 Iovance Biotherapeutics Cell Therapy for Solid Tumor Product and Solutions
2.1.4 Iovance Biotherapeutics Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Iovance Biotherapeutics Recent Developments and Future Plans
2.2 Adaptimmune
2.2.1 Adaptimmune Details
2.2.2 Adaptimmune Major Business
2.2.3 Adaptimmune Cell Therapy for Solid Tumor Product and Solutions
2.2.4 Adaptimmune Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Adaptimmune Recent Developments and Future Plans
2.3 Immatics
2.3.1 Immatics Details
2.3.2 Immatics Major Business
2.3.3 Immatics Cell Therapy for Solid Tumor Product and Solutions
2.3.4 Immatics Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Immatics Recent Developments and Future Plans
2.4 CARSgen Therapeutics
2.4.1 CARSgen Therapeutics Details
2.4.2 CARSgen Therapeutics Major Business
2.4.3 CARSgen Therapeutics Cell Therapy for Solid Tumor Product and Solutions
2.4.4 CARSgen Therapeutics Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 CARSgen Therapeutics Recent Developments and Future Plans
2.5 JW Therapeutics
2.5.1 JW Therapeutics Details
2.5.2 JW Therapeutics Major Business
2.5.3 JW Therapeutics Cell Therapy for Solid Tumor Product and Solutions
2.5.4 JW Therapeutics Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 JW Therapeutics Recent Developments and Future Plans
2.6 Legend Biotech
2.6.1 Legend Biotech Details
2.6.2 Legend Biotech Major Business
2.6.3 Legend Biotech Cell Therapy for Solid Tumor Product and Solutions
2.6.4 Legend Biotech Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 Legend Biotech Recent Developments and Future Plans
2.7 Gracell Biotechnologies
2.7.1 Gracell Biotechnologies Details
2.7.2 Gracell Biotechnologies Major Business
2.7.3 Gracell Biotechnologies Cell Therapy for Solid Tumor Product and Solutions
2.7.4 Gracell Biotechnologies Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 Gracell Biotechnologies Recent Developments and Future Plans
2.8 Fosun Kite
2.8.1 Fosun Kite Details
2.8.2 Fosun Kite Major Business
2.8.3 Fosun Kite Cell Therapy for Solid Tumor Product and Solutions
2.8.4 Fosun Kite Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 Fosun Kite Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Cell Therapy for Solid Tumor Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
3.2.1 Market Share of Cell Therapy for Solid Tumor by Company Revenue
3.2.2 Top 3 Cell Therapy for Solid Tumor Players Market Share in 2025
3.2.3 Top 6 Cell Therapy for Solid Tumor Players Market Share in 2025
3.3 Cell Therapy for Solid Tumor Market: Overall Company Footprint Analysis
3.3.1 Cell Therapy for Solid Tumor Market: Region Footprint
3.3.2 Cell Therapy for Solid Tumor Market: Company Product Type Footprint
3.3.3 Cell Therapy for Solid Tumor Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Cell Therapy for Solid Tumor Consumption Value and Market Share by Type (2021-2026)
4.2 Global Cell Therapy for Solid Tumor Market Forecast by Type (2027-2032)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Cell Therapy for Solid Tumor Consumption Value Market Share by Application (2021-2026)
5.2 Global Cell Therapy for Solid Tumor Market Forecast by Application (2027-2032)
6 NORTH AMERICA
6.1 North America Cell Therapy for Solid Tumor Consumption Value by Type (2021-2032)
6.2 North America Cell Therapy for Solid Tumor Market Size by Application (2021-2032)
6.3 North America Cell Therapy for Solid Tumor Market Size by Country
6.3.1 North America Cell Therapy for Solid Tumor Consumption Value by Country (2021-2032)
6.3.2 United States Cell Therapy for Solid Tumor Market Size and Forecast (2021-2032)
6.3.3 Canada Cell Therapy for Solid Tumor Market Size and Forecast (2021-2032)
6.3.4 Mexico Cell Therapy for Solid Tumor Market Size and Forecast (2021-2032)
7 EUROPE
7.1 Europe Cell Therapy for Solid Tumor Consumption Value by Type (2021-2032)
7.2 Europe Cell Therapy for Solid Tumor Consumption Value by Application (2021-2032)
7.3 Europe Cell Therapy for Solid Tumor Market Size by Country
7.3.1 Europe Cell Therapy for Solid Tumor Consumption Value by Country (2021-2032)
7.3.2 Germany Cell Therapy for Solid Tumor Market Size and Forecast (2021-2032)
7.3.3 France Cell Therapy for Solid Tumor Market Size and Forecast (2021-2032)
7.3.4 United Kingdom Cell Therapy for Solid Tumor Market Size and Forecast (2021-2032)
7.3.5 Russia Cell Therapy for Solid Tumor Market Size and Forecast (2021-2032)
7.3.6 Italy Cell Therapy for Solid Tumor Market Size and Forecast (2021-2032)
8 ASIA-PACIFIC
8.1 Asia-Pacific Cell Therapy for Solid Tumor Consumption Value by Type (2021-2032)
8.2 Asia-Pacific Cell Therapy for Solid Tumor Consumption Value by Application (2021-2032)
8.3 Asia-Pacific Cell Therapy for Solid Tumor Market Size by Region
8.3.1 Asia-Pacific Cell Therapy for Solid Tumor Consumption Value by Region (2021-2032)
8.3.2 China Cell Therapy for Solid Tumor Market Size and Forecast (2021-2032)
8.3.3 Japan Cell Therapy for Solid Tumor Market Size and Forecast (2021-2032)
8.3.4 South Korea Cell Therapy for Solid Tumor Market Size and Forecast (2021-2032)
8.3.5 India Cell Therapy for Solid Tumor Market Size and Forecast (2021-2032)
8.3.6 Southeast Asia Cell Therapy for Solid Tumor Market Size and Forecast (2021-2032)
8.3.7 Australia Cell Therapy for Solid Tumor Market Size and Forecast (2021-2032)
9 SOUTH AMERICA
9.1 South America Cell Therapy for Solid Tumor Consumption Value by Type (2021-2032)
9.2 South America Cell Therapy for Solid Tumor Consumption Value by Application (2021-2032)
9.3 South America Cell Therapy for Solid Tumor Market Size by Country
9.3.1 South America Cell Therapy for Solid Tumor Consumption Value by Country (2021-2032)
9.3.2 Brazil Cell Therapy for Solid Tumor Market Size and Forecast (2021-2032)
9.3.3 Argentina Cell Therapy for Solid Tumor Market Size and Forecast (2021-2032)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Cell Therapy for Solid Tumor Consumption Value by Type (2021-2032)
10.2 Middle East & Africa Cell Therapy for Solid Tumor Consumption Value by Application (2021-2032)
10.3 Middle East & Africa Cell Therapy for Solid Tumor Market Size by Country
10.3.1 Middle East & Africa Cell Therapy for Solid Tumor Consumption Value by Country (2021-2032)
10.3.2 Turkey Cell Therapy for Solid Tumor Market Size and Forecast (2021-2032)
10.3.3 Saudi Arabia Cell Therapy for Solid Tumor Market Size and Forecast (2021-2032)
10.3.4 UAE Cell Therapy for Solid Tumor Market Size and Forecast (2021-2032)
11 MARKET DYNAMICS
11.1 Cell Therapy for Solid Tumor Market Drivers
11.2 Cell Therapy for Solid Tumor Market Restraints
11.3 Cell Therapy for Solid Tumor Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Cell Therapy for Solid Tumor Industry Chain
12.2 Cell Therapy for Solid Tumor Upstream Analysis
12.3 Cell Therapy for Solid Tumor Midstream Analysis
12.4 Cell Therapy for Solid Tumor Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF TABLES
Table 1. Global Cell Therapy for Solid Tumor Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Cell Therapy for Solid Tumor Consumption Value by Cell Source, (USD Million), 2021 & 2025 & 2032
Table 3. Global Cell Therapy for Solid Tumor Consumption Value by Indication, (USD Million), 2021 & 2025 & 2032
Table 4. Global Cell Therapy for Solid Tumor Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 5. Global Cell Therapy for Solid Tumor Consumption Value by Region (2021-2026) & (USD Million)
Table 6. Global Cell Therapy for Solid Tumor Consumption Value by Region (2027-2032) & (USD Million)
Table 7. Iovance Biotherapeutics Company Information, Head Office, and Major Competitors
Table 8. Iovance Biotherapeutics Major Business
Table 9. Iovance Biotherapeutics Cell Therapy for Solid Tumor Product and Solutions
Table 10. Iovance Biotherapeutics Cell Therapy for Solid Tumor Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 11. Iovance Biotherapeutics Recent Developments and Future Plans
Table 12. Adaptimmune Company Information, Head Office, and Major Competitors
Table 13. Adaptimmune Major Business
Table 14. Adaptimmune Cell Therapy for Solid Tumor Product and Solutions
Table 15. Adaptimmune Cell Therapy for Solid Tumor Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 16. Adaptimmune Recent Developments and Future Plans
Table 17. Immatics Company Information, Head Office, and Major Competitors
Table 18. Immatics Major Business
Table 19. Immatics Cell Therapy for Solid Tumor Product and Solutions
Table 20. Immatics Cell Therapy for Solid Tumor Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 21. CARSgen Therapeutics Company Information, Head Office, and Major Competitors
Table 22. CARSgen Therapeutics Major Business
Table 23. CARSgen Therapeutics Cell Therapy for Solid Tumor Product and Solutions
Table 24. CARSgen Therapeutics Cell Therapy for Solid Tumor Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 25. CARSgen Therapeutics Recent Developments and Future Plans
Table 26. JW Therapeutics Company Information, Head Office, and Major Competitors
Table 27. JW Therapeutics Major Business
Table 28. JW Therapeutics Cell Therapy for Solid Tumor Product and Solutions
Table 29. JW Therapeutics Cell Therapy for Solid Tumor Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 30. JW Therapeutics Recent Developments and Future Plans
Table 31. Legend Biotech Company Information, Head Office, and Major Competitors
Table 32. Legend Biotech Major Business
Table 33. Legend Biotech Cell Therapy for Solid Tumor Product and Solutions
Table 34. Legend Biotech Cell Therapy for Solid Tumor Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 35. Legend Biotech Recent Developments and Future Plans
Table 36. Gracell Biotechnologies Company Information, Head Office, and Major Competitors
Table 37. Gracell Biotechnologies Major Business
Table 38. Gracell Biotechnologies Cell Therapy for Solid Tumor Product and Solutions
Table 39. Gracell Biotechnologies Cell Therapy for Solid Tumor Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 40. Gracell Biotechnologies Recent Developments and Future Plans
Table 41. Fosun Kite Company Information, Head Office, and Major Competitors
Table 42. Fosun Kite Major Business
Table 43. Fosun Kite Cell Therapy for Solid Tumor Product and Solutions
Table 44. Fosun Kite Cell Therapy for Solid Tumor Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 45. Fosun Kite Recent Developments and Future Plans
Table 46. Global Cell Therapy for Solid Tumor Revenue (USD Million) by Players (2021-2026)
Table 47. Global Cell Therapy for Solid Tumor Revenue Share by Players (2021-2026)
Table 48. Breakdown of Cell Therapy for Solid Tumor by Company Type (Tier 1, Tier 2, and Tier 3)
Table 49. Market Position of Players in Cell Therapy for Solid Tumor, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 50. Head Office of Key Cell Therapy for Solid Tumor Players
Table 51. Cell Therapy for Solid Tumor Market: Company Product Type Footprint
Table 52. Cell Therapy for Solid Tumor Market: Company Product Application Footprint
Table 53. Cell Therapy for Solid Tumor New Market Entrants and Barriers to Market Entry
Table 54. Cell Therapy for Solid Tumor Mergers, Acquisition, Agreements, and Collaborations
Table 55. Global Cell Therapy for Solid Tumor Consumption Value (USD Million) by Type (2021-2026)
Table 56. Global Cell Therapy for Solid Tumor Consumption Value Share by Type (2021-2026)
Table 57. Global Cell Therapy for Solid Tumor Consumption Value Forecast by Type (2027-2032)
Table 58. Global Cell Therapy for Solid Tumor Consumption Value by Application (2021-2026)
Table 59. Global Cell Therapy for Solid Tumor Consumption Value Forecast by Application (2027-2032)
Table 60. North America Cell Therapy for Solid Tumor Consumption Value by Type (2021-2026) & (USD Million)
Table 61. North America Cell Therapy for Solid Tumor Consumption Value by Type (2027-2032) & (USD Million)
Table 62. North America Cell Therapy for Solid Tumor Consumption Value by Application (2021-2026) & (USD Million)
Table 63. North America Cell Therapy for Solid Tumor Consumption Value by Application (2027-2032) & (USD Million)
Table 64. North America Cell Therapy for Solid Tumor Consumption Value by Country (2021-2026) & (USD Million)
Table 65. North America Cell Therapy for Solid Tumor Consumption Value by Country (2027-2032) & (USD Million)
Table 66. Europe Cell Therapy for Solid Tumor Consumption Value by Type (2021-2026) & (USD Million)
Table 67. Europe Cell Therapy for Solid Tumor Consumption Value by Type (2027-2032) & (USD Million)
Table 68. Europe Cell Therapy for Solid Tumor Consumption Value by Application (2021-2026) & (USD Million)
Table 69. Europe Cell Therapy for Solid Tumor Consumption Value by Application (2027-2032) & (USD Million)
Table 70. Europe Cell Therapy for Solid Tumor Consumption Value by Country (2021-2026) & (USD Million)
Table 71. Europe Cell Therapy for Solid Tumor Consumption Value by Country (2027-2032) & (USD Million)
Table 72. Asia-Pacific Cell Therapy for Solid Tumor Consumption Value by Type (2021-2026) & (USD Million)
Table 73. Asia-Pacific Cell Therapy for Solid Tumor Consumption Value by Type (2027-2032) & (USD Million)
Table 74. Asia-Pacific Cell Therapy for Solid Tumor Consumption Value by Application (2021-2026) & (USD Million)
Table 75. Asia-Pacific Cell Therapy for Solid Tumor Consumption Value by Application (2027-2032) & (USD Million)
Table 76. Asia-Pacific Cell Therapy for Solid Tumor Consumption Value by Region (2021-2026) & (USD Million)
Table 77. Asia-Pacific Cell Therapy for Solid Tumor Consumption Value by Region (2027-2032) & (USD Million)
Table 78. South America Cell Therapy for Solid Tumor Consumption Value by Type (2021-2026) & (USD Million)
Table 79. South America Cell Therapy for Solid Tumor Consumption Value by Type (2027-2032) & (USD Million)
Table 80. South America Cell Therapy for Solid Tumor Consumption Value by Application (2021-2026) & (USD Million)
Table 81. South America Cell Therapy for Solid Tumor Consumption Value by Application (2027-2032) & (USD Million)
Table 82. South America Cell Therapy for Solid Tumor Consumption Value by Country (2021-2026) & (USD Million)
Table 83. South America Cell Therapy for Solid Tumor Consumption Value by Country (2027-2032) & (USD Million)
Table 84. Middle East & Africa Cell Therapy for Solid Tumor Consumption Value by Type (2021-2026) & (USD Million)
Table 85. Middle East & Africa Cell Therapy for Solid Tumor Consumption Value by Type (2027-2032) & (USD Million)
Table 86. Middle East & Africa Cell Therapy for Solid Tumor Consumption Value by Application (2021-2026) & (USD Million)
Table 87. Middle East & Africa Cell Therapy for Solid Tumor Consumption Value by Application (2027-2032) & (USD Million)
Table 88. Middle East & Africa Cell Therapy for Solid Tumor Consumption Value by Country (2021-2026) & (USD Million)
Table 89. Middle East & Africa Cell Therapy for Solid Tumor Consumption Value by Country (2027-2032) & (USD Million)
Table 90. Global Key Players of Cell Therapy for Solid Tumor Upstream (Raw Materials)
Table 91. Global Cell Therapy for Solid Tumor Typical Customers
Table 1. Global Cell Therapy for Solid Tumor Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Cell Therapy for Solid Tumor Consumption Value by Cell Source, (USD Million), 2021 & 2025 & 2032
Table 3. Global Cell Therapy for Solid Tumor Consumption Value by Indication, (USD Million), 2021 & 2025 & 2032
Table 4. Global Cell Therapy for Solid Tumor Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 5. Global Cell Therapy for Solid Tumor Consumption Value by Region (2021-2026) & (USD Million)
Table 6. Global Cell Therapy for Solid Tumor Consumption Value by Region (2027-2032) & (USD Million)
Table 7. Iovance Biotherapeutics Company Information, Head Office, and Major Competitors
Table 8. Iovance Biotherapeutics Major Business
Table 9. Iovance Biotherapeutics Cell Therapy for Solid Tumor Product and Solutions
Table 10. Iovance Biotherapeutics Cell Therapy for Solid Tumor Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 11. Iovance Biotherapeutics Recent Developments and Future Plans
Table 12. Adaptimmune Company Information, Head Office, and Major Competitors
Table 13. Adaptimmune Major Business
Table 14. Adaptimmune Cell Therapy for Solid Tumor Product and Solutions
Table 15. Adaptimmune Cell Therapy for Solid Tumor Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 16. Adaptimmune Recent Developments and Future Plans
Table 17. Immatics Company Information, Head Office, and Major Competitors
Table 18. Immatics Major Business
Table 19. Immatics Cell Therapy for Solid Tumor Product and Solutions
Table 20. Immatics Cell Therapy for Solid Tumor Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 21. CARSgen Therapeutics Company Information, Head Office, and Major Competitors
Table 22. CARSgen Therapeutics Major Business
Table 23. CARSgen Therapeutics Cell Therapy for Solid Tumor Product and Solutions
Table 24. CARSgen Therapeutics Cell Therapy for Solid Tumor Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 25. CARSgen Therapeutics Recent Developments and Future Plans
Table 26. JW Therapeutics Company Information, Head Office, and Major Competitors
Table 27. JW Therapeutics Major Business
Table 28. JW Therapeutics Cell Therapy for Solid Tumor Product and Solutions
Table 29. JW Therapeutics Cell Therapy for Solid Tumor Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 30. JW Therapeutics Recent Developments and Future Plans
Table 31. Legend Biotech Company Information, Head Office, and Major Competitors
Table 32. Legend Biotech Major Business
Table 33. Legend Biotech Cell Therapy for Solid Tumor Product and Solutions
Table 34. Legend Biotech Cell Therapy for Solid Tumor Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 35. Legend Biotech Recent Developments and Future Plans
Table 36. Gracell Biotechnologies Company Information, Head Office, and Major Competitors
Table 37. Gracell Biotechnologies Major Business
Table 38. Gracell Biotechnologies Cell Therapy for Solid Tumor Product and Solutions
Table 39. Gracell Biotechnologies Cell Therapy for Solid Tumor Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 40. Gracell Biotechnologies Recent Developments and Future Plans
Table 41. Fosun Kite Company Information, Head Office, and Major Competitors
Table 42. Fosun Kite Major Business
Table 43. Fosun Kite Cell Therapy for Solid Tumor Product and Solutions
Table 44. Fosun Kite Cell Therapy for Solid Tumor Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 45. Fosun Kite Recent Developments and Future Plans
Table 46. Global Cell Therapy for Solid Tumor Revenue (USD Million) by Players (2021-2026)
Table 47. Global Cell Therapy for Solid Tumor Revenue Share by Players (2021-2026)
Table 48. Breakdown of Cell Therapy for Solid Tumor by Company Type (Tier 1, Tier 2, and Tier 3)
Table 49. Market Position of Players in Cell Therapy for Solid Tumor, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 50. Head Office of Key Cell Therapy for Solid Tumor Players
Table 51. Cell Therapy for Solid Tumor Market: Company Product Type Footprint
Table 52. Cell Therapy for Solid Tumor Market: Company Product Application Footprint
Table 53. Cell Therapy for Solid Tumor New Market Entrants and Barriers to Market Entry
Table 54. Cell Therapy for Solid Tumor Mergers, Acquisition, Agreements, and Collaborations
Table 55. Global Cell Therapy for Solid Tumor Consumption Value (USD Million) by Type (2021-2026)
Table 56. Global Cell Therapy for Solid Tumor Consumption Value Share by Type (2021-2026)
Table 57. Global Cell Therapy for Solid Tumor Consumption Value Forecast by Type (2027-2032)
Table 58. Global Cell Therapy for Solid Tumor Consumption Value by Application (2021-2026)
Table 59. Global Cell Therapy for Solid Tumor Consumption Value Forecast by Application (2027-2032)
Table 60. North America Cell Therapy for Solid Tumor Consumption Value by Type (2021-2026) & (USD Million)
Table 61. North America Cell Therapy for Solid Tumor Consumption Value by Type (2027-2032) & (USD Million)
Table 62. North America Cell Therapy for Solid Tumor Consumption Value by Application (2021-2026) & (USD Million)
Table 63. North America Cell Therapy for Solid Tumor Consumption Value by Application (2027-2032) & (USD Million)
Table 64. North America Cell Therapy for Solid Tumor Consumption Value by Country (2021-2026) & (USD Million)
Table 65. North America Cell Therapy for Solid Tumor Consumption Value by Country (2027-2032) & (USD Million)
Table 66. Europe Cell Therapy for Solid Tumor Consumption Value by Type (2021-2026) & (USD Million)
Table 67. Europe Cell Therapy for Solid Tumor Consumption Value by Type (2027-2032) & (USD Million)
Table 68. Europe Cell Therapy for Solid Tumor Consumption Value by Application (2021-2026) & (USD Million)
Table 69. Europe Cell Therapy for Solid Tumor Consumption Value by Application (2027-2032) & (USD Million)
Table 70. Europe Cell Therapy for Solid Tumor Consumption Value by Country (2021-2026) & (USD Million)
Table 71. Europe Cell Therapy for Solid Tumor Consumption Value by Country (2027-2032) & (USD Million)
Table 72. Asia-Pacific Cell Therapy for Solid Tumor Consumption Value by Type (2021-2026) & (USD Million)
Table 73. Asia-Pacific Cell Therapy for Solid Tumor Consumption Value by Type (2027-2032) & (USD Million)
Table 74. Asia-Pacific Cell Therapy for Solid Tumor Consumption Value by Application (2021-2026) & (USD Million)
Table 75. Asia-Pacific Cell Therapy for Solid Tumor Consumption Value by Application (2027-2032) & (USD Million)
Table 76. Asia-Pacific Cell Therapy for Solid Tumor Consumption Value by Region (2021-2026) & (USD Million)
Table 77. Asia-Pacific Cell Therapy for Solid Tumor Consumption Value by Region (2027-2032) & (USD Million)
Table 78. South America Cell Therapy for Solid Tumor Consumption Value by Type (2021-2026) & (USD Million)
Table 79. South America Cell Therapy for Solid Tumor Consumption Value by Type (2027-2032) & (USD Million)
Table 80. South America Cell Therapy for Solid Tumor Consumption Value by Application (2021-2026) & (USD Million)
Table 81. South America Cell Therapy for Solid Tumor Consumption Value by Application (2027-2032) & (USD Million)
Table 82. South America Cell Therapy for Solid Tumor Consumption Value by Country (2021-2026) & (USD Million)
Table 83. South America Cell Therapy for Solid Tumor Consumption Value by Country (2027-2032) & (USD Million)
Table 84. Middle East & Africa Cell Therapy for Solid Tumor Consumption Value by Type (2021-2026) & (USD Million)
Table 85. Middle East & Africa Cell Therapy for Solid Tumor Consumption Value by Type (2027-2032) & (USD Million)
Table 86. Middle East & Africa Cell Therapy for Solid Tumor Consumption Value by Application (2021-2026) & (USD Million)
Table 87. Middle East & Africa Cell Therapy for Solid Tumor Consumption Value by Application (2027-2032) & (USD Million)
Table 88. Middle East & Africa Cell Therapy for Solid Tumor Consumption Value by Country (2021-2026) & (USD Million)
Table 89. Middle East & Africa Cell Therapy for Solid Tumor Consumption Value by Country (2027-2032) & (USD Million)
Table 90. Global Key Players of Cell Therapy for Solid Tumor Upstream (Raw Materials)
Table 91. Global Cell Therapy for Solid Tumor Typical Customers
LIST OF FIGURES
Figure 1. Cell Therapy for Solid Tumor Picture
Figure 2. Global Cell Therapy for Solid Tumor Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Cell Therapy for Solid Tumor Consumption Value Market Share by Type in 2025
Figure 4. CAR-T Therapy
Figure 5. TCR-T Therapy
Figure 6. TIL Therapy
Figure 7. CAR-NK Therapy
Figure 8. Tumor-Infiltrating NK Or T Cells
Figure 9. Other
Figure 10. Global Cell Therapy for Solid Tumor Consumption Value by Cell Source, (USD Million), 2021 & 2025 & 2032
Figure 11. Global Cell Therapy for Solid Tumor Consumption Value Market Share by Cell Source in 2025
Figure 12. Autologous Therapy
Figure 13. Allogeneic Therapy
Figure 14. Gene-Edited Therapy
Figure 15. Armored Cell Therapy
Figure 16. Combination Therapy
Figure 17. Other
Figure 18. Global Cell Therapy for Solid Tumor Consumption Value by Indication, (USD Million), 2021 & 2025 & 2032
Figure 19. Global Cell Therapy for Solid Tumor Consumption Value Market Share by Indication in 2025
Figure 20. Melanoma Products
Figure 21. Gastrointestinal Tumor Products
Figure 22. Liver Cancer Products
Figure 23. Lung Cancer Products
Figure 24. Gynecologic Tumor Products
Figure 25. Other
Figure 26. Global Cell Therapy for Solid Tumor Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 27. Cell Therapy for Solid Tumor Consumption Value Market Share by Application in 2025
Figure 28. Melanoma Picture
Figure 29. Lung Cancer Picture
Figure 30. Liver Cancer Picture
Figure 31. Gastric And Colorectal Cancer Picture
Figure 32. Ovarian Cancer Picture
Figure 33. Other Picture
Figure 34. Global Cell Therapy for Solid Tumor Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 35. Global Cell Therapy for Solid Tumor Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 36. Global Market Cell Therapy for Solid Tumor Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)
Figure 37. Global Cell Therapy for Solid Tumor Consumption Value Market Share by Region (2021-2032)
Figure 38. Global Cell Therapy for Solid Tumor Consumption Value Market Share by Region in 2025
Figure 39. North America Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 40. Europe Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 41. Asia-Pacific Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 42. South America Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 43. Middle East & Africa Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 44. Company Three Recent Developments and Future Plans
Figure 45. Global Cell Therapy for Solid Tumor Revenue Share by Players in 2025
Figure 46. Cell Therapy for Solid Tumor Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025
Figure 47. Market Share of Cell Therapy for Solid Tumor by Player Revenue in 2025
Figure 48. Top 3 Cell Therapy for Solid Tumor Players Market Share in 2025
Figure 49. Top 6 Cell Therapy for Solid Tumor Players Market Share in 2025
Figure 50. Global Cell Therapy for Solid Tumor Consumption Value Share by Type (2021-2026)
Figure 51. Global Cell Therapy for Solid Tumor Market Share Forecast by Type (2027-2032)
Figure 52. Global Cell Therapy for Solid Tumor Consumption Value Share by Application (2021-2026)
Figure 53. Global Cell Therapy for Solid Tumor Market Share Forecast by Application (2027-2032)
Figure 54. North America Cell Therapy for Solid Tumor Consumption Value Market Share by Type (2021-2032)
Figure 55. North America Cell Therapy for Solid Tumor Consumption Value Market Share by Application (2021-2032)
Figure 56. North America Cell Therapy for Solid Tumor Consumption Value Market Share by Country (2021-2032)
Figure 57. United States Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 58. Canada Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 59. Mexico Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 60. Europe Cell Therapy for Solid Tumor Consumption Value Market Share by Type (2021-2032)
Figure 61. Europe Cell Therapy for Solid Tumor Consumption Value Market Share by Application (2021-2032)
Figure 62. Europe Cell Therapy for Solid Tumor Consumption Value Market Share by Country (2021-2032)
Figure 63. Germany Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 64. France Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 65. United Kingdom Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 66. Russia Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 67. Italy Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 68. Asia-Pacific Cell Therapy for Solid Tumor Consumption Value Market Share by Type (2021-2032)
Figure 69. Asia-Pacific Cell Therapy for Solid Tumor Consumption Value Market Share by Application (2021-2032)
Figure 70. Asia-Pacific Cell Therapy for Solid Tumor Consumption Value Market Share by Region (2021-2032)
Figure 71. China Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 72. Japan Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 73. South Korea Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 74. India Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 75. Southeast Asia Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 76. Australia Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 77. South America Cell Therapy for Solid Tumor Consumption Value Market Share by Type (2021-2032)
Figure 78. South America Cell Therapy for Solid Tumor Consumption Value Market Share by Application (2021-2032)
Figure 79. South America Cell Therapy for Solid Tumor Consumption Value Market Share by Country (2021-2032)
Figure 80. Brazil Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 81. Argentina Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 82. Middle East & Africa Cell Therapy for Solid Tumor Consumption Value Market Share by Type (2021-2032)
Figure 83. Middle East & Africa Cell Therapy for Solid Tumor Consumption Value Market Share by Application (2021-2032)
Figure 84. Middle East & Africa Cell Therapy for Solid Tumor Consumption Value Market Share by Country (2021-2032)
Figure 85. Turkey Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 86. Saudi Arabia Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 87. UAE Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 88. Cell Therapy for Solid Tumor Market Drivers
Figure 89. Cell Therapy for Solid Tumor Market Restraints
Figure 90. Cell Therapy for Solid Tumor Market Trends
Figure 91. Porters Five Forces Analysis
Figure 92. Cell Therapy for Solid Tumor Industrial Chain
Figure 93. Methodology
Figure 94. Research Process and Data Source
Figure 1. Cell Therapy for Solid Tumor Picture
Figure 2. Global Cell Therapy for Solid Tumor Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Cell Therapy for Solid Tumor Consumption Value Market Share by Type in 2025
Figure 4. CAR-T Therapy
Figure 5. TCR-T Therapy
Figure 6. TIL Therapy
Figure 7. CAR-NK Therapy
Figure 8. Tumor-Infiltrating NK Or T Cells
Figure 9. Other
Figure 10. Global Cell Therapy for Solid Tumor Consumption Value by Cell Source, (USD Million), 2021 & 2025 & 2032
Figure 11. Global Cell Therapy for Solid Tumor Consumption Value Market Share by Cell Source in 2025
Figure 12. Autologous Therapy
Figure 13. Allogeneic Therapy
Figure 14. Gene-Edited Therapy
Figure 15. Armored Cell Therapy
Figure 16. Combination Therapy
Figure 17. Other
Figure 18. Global Cell Therapy for Solid Tumor Consumption Value by Indication, (USD Million), 2021 & 2025 & 2032
Figure 19. Global Cell Therapy for Solid Tumor Consumption Value Market Share by Indication in 2025
Figure 20. Melanoma Products
Figure 21. Gastrointestinal Tumor Products
Figure 22. Liver Cancer Products
Figure 23. Lung Cancer Products
Figure 24. Gynecologic Tumor Products
Figure 25. Other
Figure 26. Global Cell Therapy for Solid Tumor Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 27. Cell Therapy for Solid Tumor Consumption Value Market Share by Application in 2025
Figure 28. Melanoma Picture
Figure 29. Lung Cancer Picture
Figure 30. Liver Cancer Picture
Figure 31. Gastric And Colorectal Cancer Picture
Figure 32. Ovarian Cancer Picture
Figure 33. Other Picture
Figure 34. Global Cell Therapy for Solid Tumor Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 35. Global Cell Therapy for Solid Tumor Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 36. Global Market Cell Therapy for Solid Tumor Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)
Figure 37. Global Cell Therapy for Solid Tumor Consumption Value Market Share by Region (2021-2032)
Figure 38. Global Cell Therapy for Solid Tumor Consumption Value Market Share by Region in 2025
Figure 39. North America Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 40. Europe Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 41. Asia-Pacific Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 42. South America Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 43. Middle East & Africa Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 44. Company Three Recent Developments and Future Plans
Figure 45. Global Cell Therapy for Solid Tumor Revenue Share by Players in 2025
Figure 46. Cell Therapy for Solid Tumor Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025
Figure 47. Market Share of Cell Therapy for Solid Tumor by Player Revenue in 2025
Figure 48. Top 3 Cell Therapy for Solid Tumor Players Market Share in 2025
Figure 49. Top 6 Cell Therapy for Solid Tumor Players Market Share in 2025
Figure 50. Global Cell Therapy for Solid Tumor Consumption Value Share by Type (2021-2026)
Figure 51. Global Cell Therapy for Solid Tumor Market Share Forecast by Type (2027-2032)
Figure 52. Global Cell Therapy for Solid Tumor Consumption Value Share by Application (2021-2026)
Figure 53. Global Cell Therapy for Solid Tumor Market Share Forecast by Application (2027-2032)
Figure 54. North America Cell Therapy for Solid Tumor Consumption Value Market Share by Type (2021-2032)
Figure 55. North America Cell Therapy for Solid Tumor Consumption Value Market Share by Application (2021-2032)
Figure 56. North America Cell Therapy for Solid Tumor Consumption Value Market Share by Country (2021-2032)
Figure 57. United States Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 58. Canada Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 59. Mexico Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 60. Europe Cell Therapy for Solid Tumor Consumption Value Market Share by Type (2021-2032)
Figure 61. Europe Cell Therapy for Solid Tumor Consumption Value Market Share by Application (2021-2032)
Figure 62. Europe Cell Therapy for Solid Tumor Consumption Value Market Share by Country (2021-2032)
Figure 63. Germany Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 64. France Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 65. United Kingdom Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 66. Russia Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 67. Italy Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 68. Asia-Pacific Cell Therapy for Solid Tumor Consumption Value Market Share by Type (2021-2032)
Figure 69. Asia-Pacific Cell Therapy for Solid Tumor Consumption Value Market Share by Application (2021-2032)
Figure 70. Asia-Pacific Cell Therapy for Solid Tumor Consumption Value Market Share by Region (2021-2032)
Figure 71. China Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 72. Japan Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 73. South Korea Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 74. India Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 75. Southeast Asia Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 76. Australia Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 77. South America Cell Therapy for Solid Tumor Consumption Value Market Share by Type (2021-2032)
Figure 78. South America Cell Therapy for Solid Tumor Consumption Value Market Share by Application (2021-2032)
Figure 79. South America Cell Therapy for Solid Tumor Consumption Value Market Share by Country (2021-2032)
Figure 80. Brazil Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 81. Argentina Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 82. Middle East & Africa Cell Therapy for Solid Tumor Consumption Value Market Share by Type (2021-2032)
Figure 83. Middle East & Africa Cell Therapy for Solid Tumor Consumption Value Market Share by Application (2021-2032)
Figure 84. Middle East & Africa Cell Therapy for Solid Tumor Consumption Value Market Share by Country (2021-2032)
Figure 85. Turkey Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 86. Saudi Arabia Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 87. UAE Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 88. Cell Therapy for Solid Tumor Market Drivers
Figure 89. Cell Therapy for Solid Tumor Market Restraints
Figure 90. Cell Therapy for Solid Tumor Market Trends
Figure 91. Porters Five Forces Analysis
Figure 92. Cell Therapy for Solid Tumor Industrial Chain
Figure 93. Methodology
Figure 94. Research Process and Data Source
